A brighter future
MAGIC-G1 Clinical Trial for patients suffering with recurrent glioblastoma
Currently open for recruitment at two US hospitals, in North Carolina and Florida, the MAGIC-G1 trial is a phase I study investigating the safety of an experimental drug known as MTX110. In the MAGIC-G1 clinical trial, MTX110 is administered directly to the site of the tumor using a technique called convection-enhanced delivery (CED).
Expanded Access Policy
Reports & Presentations